AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for KRAS P.G12D

A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation NCT07784374Phase 21 site๐Ÿ“ Shanghai Genfleet Therapeutics (Shanghai) Inc. ยท Tests: GFH375, GFH276, GFS202A A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation. NCT07456046Phase 19 sites๐Ÿ“ New Haven๐Ÿ“ Houston๐Ÿ“ San Antonio D3 Bio (Wuxi) Co., Ltd ยท Tests: D3S-003 A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer NCT07659782Phase 224 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Verastem, Inc. ยท Tests: VS-7375 BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites๐Ÿ“ Los Angeles๐Ÿ“ Sacramento๐Ÿ“ San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) ยท Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07610798Phase 1, Phase 21 site๐Ÿ“ Guangzhou Shenzhen Ionova Life Sciences Co., Ltd. ยท Tests: INV-8989 A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer NCT07409272Phase 379 sites๐Ÿ“ Tucson๐Ÿ“ Fort Smith๐Ÿ“ Fullerton Astellas Pharma Global Development, Inc. ยท Tests: Setidegrasib, Oxaliplatin, Leucovorin, Irinotecan, fluorouracil A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation NCT07535112Phase 121 sites๐Ÿ“ Phoenix๐Ÿ“ Duarte๐Ÿ“ San Diego Bayer ยท Tests: BAY 3771249, Cetuximab Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites๐Ÿ“ Sacramento๐Ÿ“ New Haven๐Ÿ“ Sarasota Revolution Medicines, Inc. ยท Tests: RMC-9805, RMC-6236 Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ Newport Beach AstraZeneca ยท Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer NCT07659795Phase 230 sites๐Ÿ“ Scottsdale๐Ÿ“ Los Angeles๐Ÿ“ Los Angeles Verastem, Inc. ยท Tests: VS-7375, cetuximab, panitumumab, Cetuximab + mFOLFOX6 A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation NCT07259590Phase 1, Phase 24 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou๐Ÿ“ Zhengzhou Genfleet Therapeutics (Shanghai) Inc. ยท Tests: GFH375, GFH375 A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites๐Ÿ“ Santa Monica๐Ÿ“ Atlanta๐Ÿ“ Jefferson Astellas Pharma Inc ยท Tests: ASP5834, panitumumab A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160Phase 134 sites๐Ÿ“ Phoenix๐Ÿ“ Palo Alto๐Ÿ“ Santa Monica Incyte Corporation ยท Tests: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) NCT07621718Phase 319 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ New Haven Revolution Medicines, Inc. ยท Tests: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil Imatinib and Trametinib for KRAS-mutated Solid Tumor NCT06962254Phase 11 site๐Ÿ“ Taichung China Medical University Hospital ยท Tests: Imatinib, Trametinib A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors NCT06797336Phase 115 sites๐Ÿ“ Los Angeles๐Ÿ“ Boston๐Ÿ“ Grand Rapids PAQ Therapeutics, Inc. ยท Tests: PT0253, Chemotherapy Combination 1, Chemotherapy Combination 2, Chemotherapy Combination 3, Cetuximab Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma NCT07805954Phase 35 sites๐Ÿ“ Phoenix๐Ÿ“ Scottsdale๐Ÿ“ Jacksonville Revolution Medicines, Inc. ยท Tests: daraxonrasib, gemcitabine, nab-paclitaxel, zoldonrasib HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer NCT07232875Phase 31 site๐Ÿ“ Shanghai Jiangsu HengRui Medicine Co., Ltd. ยท Tests: HRS-4642 + AG, HRS-4642 placebo + AG Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer NCT07262567Phase 31 site๐Ÿ“ Beijing Genfleet Therapeutics (Shanghai) Inc. ยท Tests: GFH375, Chemotherapy JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration NCT06973564Phase 1, Phase 24 sites๐Ÿ“ Rochester๐Ÿ“ St Louis๐Ÿ“ Cleveland Jacobio Pharmaceuticals Co., Ltd. ยท Tests: JAB-23E73, Cetuximab A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) NCT07417189Phase 1, Phase 21 site๐Ÿ“ Shanghai Abbisko Therapeutics Co, Ltd ยท Tests: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg, ABSK141-Recommended Phase 2โ€ฆ A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors NCT06403735Phase 15 sites๐Ÿ“ Guangzhou๐Ÿ“ Harbin๐Ÿ“ Nanchang Qilu Pharmaceutical Co., Ltd. ยท Tests: QLC1101 Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07134998Phase 12 sites๐Ÿ“ Shanghai๐Ÿ“ Chengdu Jiangsu HengRui Medicine Co., Ltd. ยท Tests: HRS-6093 A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration NCT06959615Phase 1, Phase 232 sites๐Ÿ“ Hefei๐Ÿ“ Beijing๐Ÿ“ Beijing Jacobio Pharmaceuticals Co., Ltd. ยท Tests: JAB-23E73, JAB-23E73 RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors NCT06546150Phase 11 site๐Ÿ“ Zhengzhou Henan Cancer Hospital ยท Tests: RE002 T cell A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma NCT07522073Phase 3230 sites๐Ÿ“ Birmingham๐Ÿ“ Anchorage๐Ÿ“ Chandler Incyte Corporation ยท Tests: INCB161734, Placebo, Investigator's choice of chemotherapy A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221Phase 1, Phase 220 sites๐Ÿ“ Los Angeles๐Ÿ“ Baltimore๐Ÿ“ Boston Verastem, Inc. ยท Tests: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766Phase 22 sites๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou Zhejiang University ยท Tests: HRS-4642+AG+Nimotuzumab A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation NCT07566052Phase 323 sites๐Ÿ“ Glendale๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Astellas Pharma Global Development, Inc. ยท Tests: Setidegrasib, Docetaxel A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies NCT07207707Phase 113 sites๐Ÿ“ La Jolla๐Ÿ“ Los Angeles๐Ÿ“ Denver Kumquat Biosciences Inc. ยท Tests: KQB548
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy